Search

Your search keyword '"Tang, W.H. Wilson"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Tang, W.H. Wilson" Remove constraint Author: "Tang, W.H. Wilson" Topic heart failure Remove constraint Topic: heart failure
165 results on '"Tang, W.H. Wilson"'

Search Results

2. Pulmonary hypertension across the spectrum of left heart and lung disease.

3. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF.

4. Effects of Pirfenidone on Echocardiographic Parameters of Left Ventricular Structure and Function in Patients with Idiopathic Pulmonary Fibrosis

5. Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling.

6. Prognostic value of gut microbe‐generated metabolite phenylacetylglutamine in patients with heart failure.

7. The utilization and impact of cardiovascular specialists on guideline‐directed medical scores: An analysis of a diverse, multi‐state, electronic health record‐based registry.

9. Renal perturbations with sodium–glucose cotransporter 2 inhibitor in heart failure with preserved ejection fraction.

10. Sodium and potassium changes during decongestion with acetazolamide – A pre‐specified analysis from the ADVOR trial.

13. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.

14. NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?

15. The effect of intravenous ferric carboxymaltose on right ventricular function – insights from the IRON‐CRT trial.

16. Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology.

17. Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia.

18. Impact of Cardiac Resynchronization Therapy on Global and Cardiac Metabolism and Cardiac Mitochondrial Function.

19. Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure.

20. Cystatin C and Muscle Mass in Patients With Heart Failure.

21. Impact of body mass index on surgical coronary revascularization for ischaemic heart failure: insights from STICHES.

22. Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers.

24. Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.

25. Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology.

26. Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction.

27. Phenomapping of patients with heart failure with preserved ejection fraction using machine learning-based unsupervised cluster analysis.

28. A Test in Context Critical Evaluation of Natriuretic Peptide Testing in Heart Failure

29. Identifying sodium non‐excretors: heart failure's emerging golden ticket for risk stratification.

30. Impact of bariatric surgery on heart failure mortality.

31. Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.

32. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.

33. Prognostic Value of Elevated Levels of Intestinal Microbe-Generated Metabolite Trimethylamine-N-oxide in Patients with Heart Failure: Refining the Gut Hypothesis

34. Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: Practical considerations from published data

36. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.

38. Polyunsaturated Fatty Acids in Heart Failure: Should We Give More and Give Earlier?

39. High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure.

40. Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial.

41. Hemodynamic Profiling and Prognosis in Cardiac Amyloidosis.

42. Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF.

44. Temporal association between hospitalization event and subsequent risk of mortality among patients with stable chronic heart failure with preserved ejection fraction: insights from the TOPCAT trial.

45. Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure.

46. Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium.

47. Hypochloraemia is strongly and independently associated with mortality in patients with chronic heart failure.

48. Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments.

49. Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure.

50. Prognostic Value of Elevated Serum Ceruloplasmin Levels in Patients With Heart Failure.

Catalog

Books, media, physical & digital resources